Actively Recruiting
GM-CSF With Post-Transplant Cyclophosphamide
Led by Northside Hospital, Inc. · Updated on 2026-04-16
38
Participants Needed
1
Research Sites
330 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering risk of infectious complications.
CONDITIONS
Official Title
GM-CSF With Post-Transplant Cyclophosphamide
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Availability of 5/10 to 8/10 matched related donor
- Karnofsky Performance Status (KPS) of 70% or higher
- Diagnosis of CML, AML, MDS, ALL, CLL, HD, NHL, MPS/CMML, MM, or other hematologic condition eligible for allogeneic transplant as determined by treating center
You will not qualify if you...
- Poor cardiac, pulmonary, liver, or renal function
- HIV-positive status
- Debilitating medical or psychiatric illness preventing informed consent
- History of severe allergic reaction to human GM-CSF or yeast-derived products
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Northside Hospital
Atlanta, Georgia, United States, 30342
Actively Recruiting
Research Team
S
Stacey Brown, BA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here